Scholarlink

<p>Corylin, a natural flavonoid from <i>Psoralea corylifolia</i> (PC), has shown promise in the treatment of osteoporosis (OP) but the underlying mechanisms are unclear. This study aims to elucidate these mechanisms using network pharmacology, bioinformatics, molecular docking and in vitro experiments. Firstly, 213 potential therapeutic targets and 44 key targets were identified. Using the CytoHubba plugin, we screened the top 10 hub genes, including MMP9, BCL2, PPARG, PTGS2 and TNF, and others. Secondly, we identified that the MAPK, HIF-1, and Ras signaling pathways were highly enriched through enrichment analysis. The high enrichment of the MAPK pathway was further validated through transcriptomic analysis. Additionally, molecular dynamic simulation verified the formation of stable complexes between corylin and MMP9, PPARG, and PTGS2. Finally, we conducted in vivo and in vitro experiments to verify the effects of corylin on OP. In vitro, corylin (IC<sub>50</sub> = 10.79) significantly impaired cell proliferation, migration, and apoptosis. Western blot analysis revealed that the levels of P-MEK1/2, ATF1, P-JNK, P-ERK1/2, and BCL2 were significantly reduced, while Cleaved-Caspase3, PARP1, Bax, and Cleaved-Caspase7 were increased. Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) assays confirmed the upstream signals RANK/TRAF6, and p-MEK ELISA detection further validated the binding to MAPK pathway proteins. In vivo, corylin treatment ameliorated the deterioration of bone microarchitecture in an OP rat model. Additionally, corylin modulated serum bone turnover markers CTX-1 and P1NP. Overall, our findings demonstrate that corylin inhibits the MAPK pathway, inducing osteoclast apoptosis and identifying it as a promising therapeutic candidate for OP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated analysis of Corylin from Psoralea Corylifolia inhibiting osteoporosis via MAPK pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Na Liu,
  • Zhaojie Yang,
  • Ruoping Yanzhang,
  • Ruifang Shen,
  • Wengang Yi,
  • Junyan Teng

摘要

Corylin, a natural flavonoid from Psoralea corylifolia (PC), has shown promise in the treatment of osteoporosis (OP) but the underlying mechanisms are unclear. This study aims to elucidate these mechanisms using network pharmacology, bioinformatics, molecular docking and in vitro experiments. Firstly, 213 potential therapeutic targets and 44 key targets were identified. Using the CytoHubba plugin, we screened the top 10 hub genes, including MMP9, BCL2, PPARG, PTGS2 and TNF, and others. Secondly, we identified that the MAPK, HIF-1, and Ras signaling pathways were highly enriched through enrichment analysis. The high enrichment of the MAPK pathway was further validated through transcriptomic analysis. Additionally, molecular dynamic simulation verified the formation of stable complexes between corylin and MMP9, PPARG, and PTGS2. Finally, we conducted in vivo and in vitro experiments to verify the effects of corylin on OP. In vitro, corylin (IC50 = 10.79) significantly impaired cell proliferation, migration, and apoptosis. Western blot analysis revealed that the levels of P-MEK1/2, ATF1, P-JNK, P-ERK1/2, and BCL2 were significantly reduced, while Cleaved-Caspase3, PARP1, Bax, and Cleaved-Caspase7 were increased. Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) assays confirmed the upstream signals RANK/TRAF6, and p-MEK ELISA detection further validated the binding to MAPK pathway proteins. In vivo, corylin treatment ameliorated the deterioration of bone microarchitecture in an OP rat model. Additionally, corylin modulated serum bone turnover markers CTX-1 and P1NP. Overall, our findings demonstrate that corylin inhibits the MAPK pathway, inducing osteoclast apoptosis and identifying it as a promising therapeutic candidate for OP.